BioCentury
ARTICLE | Clinical News

DPX-Survivac: Additional Phase I/II data

September 5, 2016 7:00 AM UTC

Additional data from the open-label, dose-ranging Phase I/Ib portion of a North American Phase I/II trial in 54 evaluable patients with stage IIc-IV ovarian cancer showed that subcutaneous DPX-Survivac in combination with low-dose cyclophosphamide led to targeted T cell responses to the survivin protein in 87% of patients. Of 47 evaluable patients who generated T cell responses, 79% maintained “durable immune responses” over time with repeated DPX-Survivac injections. Of 18 evaluable patients who completed the 3-dose Phase I portion, 50% achieved PFS for >=24 months, including 3 patients achieving PFS for >5 years. Additionally, 1 patient demonstrated increased levels of inhibitory checkpoint molecules after treatment. Immunovaccine said the optimal dosing schedule of DPX-Survivac consists of 2 priming injections followed by booster treatment every 8 weeks for up to 1 year. The company previously reported data from the trial (see BioCentury, July 2, 2012; Oct. 15, 2012; Jan. 14, 2013 & May 26, 2014). ...